TLR9 and psoriasis: A study conducted in 478 patients of Danish origin with moderate-to-severe psoriasis treated with anti-TNF drugs (n = 376) and/or UTK (n = 230) showed that patients carrying the TLR9 rs352139-G showed greater effectiveness of anti-TNF treatment (drug survival at 225 days) (OR = 2.42, CI95% = 1.32–4.44, p = 0.0044, q = 0.19) [71].